Radiology:放射组学模型,让临床I期肺腺癌无处遁形!

2022-01-02 shaosai MedSci原创

肺癌最常见的癌症之一,也是全世界癌症死亡的主要原因。其中,腺癌是最常见的组织学亚型。手术切除为早期肺癌患者的长期生存和治愈提供了最佳机会,生存率可在53-69%之间。

肺癌最常见的癌症之一,也是全世界癌症死亡的主要原因。其中腺癌是最常见的组织学亚型。手术切除为早期肺癌患者的长期生存和治愈提供了最佳机会,生存率可在53-69%之间。然而,30-55%的肺癌患者在进行了根治性手术后仍会出现复发并死亡。虽然肿瘤TNM分期是现阶段最常用的分期手段,但由于异质性,即使在同一阶段也有不同的预后,因此对患者进行精确的分层仍存在局限性。

最近,基于影像的放射组学作为量化肿瘤异质性的新兴手段越来越引起人们的关注,并可能为患者分层提供潜在的临床成像特征。已有研究表明,可利用放射组学预测恶性病变的局部浸润和远处转移。然而,以往的研究并没有具体说明病理亚型、临床分期、治疗方法和肺癌的一致性对预后的影响。即使病理亚型和分期相同,表现为亚实性结节的肺癌的预后也比表现为实性结节的肺癌的预后要好得多。

近日,发表在Radiology杂志的一项研究利用基于包括肿瘤和瘤周区域的不同的兴趣区(VOIs)建立的CT放射组学模型评估其在临床I期实体肺腺癌中提高预后的准确性,为临床提供更精确的指导意见并协助临床更准确地预测早期肺癌患者的预后,并更早地制定个体化和精细化的治疗方案提供数据支持

本项回顾性研究包括来自两家医院(中心1和中心2)的临床I期实体肺腺癌术后患者。产生了三个数据库:数据集A(来自中心1的训练集),数据集B(来自中心1的内部测试集),以及数据集C(来自中心2的外部验证测试)。同时收集了无病生存(DFS)数据。基于四个VOIs构建CT放射组学模型:肿瘤总体积(GTV)、肿瘤边界外3毫米(肿瘤周围体积[PTV]0~+3)、跨越肿瘤边界6毫米(PTV-3~+3)和肿瘤边界外6毫米(PTV0~+6)。受试者工作曲线下的面积(AUC)被用来比较模型的准确性。 

共纳入334名患者(1号和2号中心分别为204名和130名)。在数据集B和C中,使用PTV-3~+3的模型(AUC为0.81[95%置信区间{CI}:0.75,0.94],数据集B和C为0.81[0.63,0.90])优于其他三个模型,分别为GTV(0.73 [0.58, 0.81], 0.73 [0.58, 0.83]), PTV0~+3(0.76 [0.52, 0.87], 0.75 [0.60, 0.83])和PTV0~+6(0.72 [0.60, 0.81], 0.69 [0.59, 0.81]) ,所有p<0.05。 

 

 按四个区域对选定的放射组学特征进行多变量Cox回归分析:aGTV,bPTV0~+3,cPTV-3~+3,dPTV0~+6。.表示p<0.05,*表示p<0.01,**表示p<0.001,***表示p<0.0001,经DeLong检验确定。

本研究表明,与基于瘤内、瘤外3mm或6mm的VOI相比,基于可见肿瘤边界6mm的VOI(PTV-3~+3)的放射组学模型在预测临床I期实体肺腺癌的预后方面更为准确。本研究提出的放射组学模型带来的附加信息在术前对规划干预范围和后续治疗十分有价值

原文出处

Kunfeng Liu,Kunwei Li,Tingfan Wu,et al.Improving the accuracy of prognosis for clinical stage I solid lung adenocarcinoma by radiomics models covering tumor per se and peritumoral changes on CT.DOI:10.1007/s00330-021-08194-0

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1179931, encodeId=72ee11e9931e5, content=别嘌呤醇是一种著名的黄嘌呤氧化酶抑制剂, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Jan 03 08:31:57 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179834, encodeId=9c4211e983458, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4052402179, createdName=123585fam71暂无昵称, createdTime=Sun Jan 02 19:12:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179811, encodeId=46f911e981115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210424/75ca38f652414914af9cbfb5b446886f/ea6e0bf538564d608b3eecda251c149e.jpg, createdBy=58765422551, createdName=ms5000001465822468, createdTime=Sun Jan 02 16:30:28 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179793, encodeId=195b11e979305, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Jan 02 14:46:29 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-03 查查佳佳

    别嘌呤醇是一种著名的黄嘌呤氧化酶抑制剂

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1179931, encodeId=72ee11e9931e5, content=别嘌呤醇是一种著名的黄嘌呤氧化酶抑制剂, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Jan 03 08:31:57 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179834, encodeId=9c4211e983458, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4052402179, createdName=123585fam71暂无昵称, createdTime=Sun Jan 02 19:12:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179811, encodeId=46f911e981115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210424/75ca38f652414914af9cbfb5b446886f/ea6e0bf538564d608b3eecda251c149e.jpg, createdBy=58765422551, createdName=ms5000001465822468, createdTime=Sun Jan 02 16:30:28 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179793, encodeId=195b11e979305, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Jan 02 14:46:29 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-02 123585fam71暂无昵称

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1179931, encodeId=72ee11e9931e5, content=别嘌呤醇是一种著名的黄嘌呤氧化酶抑制剂, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Jan 03 08:31:57 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179834, encodeId=9c4211e983458, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4052402179, createdName=123585fam71暂无昵称, createdTime=Sun Jan 02 19:12:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179811, encodeId=46f911e981115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210424/75ca38f652414914af9cbfb5b446886f/ea6e0bf538564d608b3eecda251c149e.jpg, createdBy=58765422551, createdName=ms5000001465822468, createdTime=Sun Jan 02 16:30:28 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179793, encodeId=195b11e979305, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Jan 02 14:46:29 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-02 ms5000001465822468

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1179931, encodeId=72ee11e9931e5, content=别嘌呤醇是一种著名的黄嘌呤氧化酶抑制剂, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Jan 03 08:31:57 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179834, encodeId=9c4211e983458, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4052402179, createdName=123585fam71暂无昵称, createdTime=Sun Jan 02 19:12:07 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179811, encodeId=46f911e981115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210424/75ca38f652414914af9cbfb5b446886f/ea6e0bf538564d608b3eecda251c149e.jpg, createdBy=58765422551, createdName=ms5000001465822468, createdTime=Sun Jan 02 16:30:28 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179793, encodeId=195b11e979305, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Jan 02 14:46:29 CST 2022, time=2022-01-02, status=1, ipAttribution=)]
    2022-01-02 weigq

    👍👍👍

    0

相关资讯

Radiology:放射组学在预测早期HCC复发中的应用

肝细胞肝癌(HCC)是全球第六大主要癌症,也是全球第二大致命肿瘤。

Euro Radio:放射组学在预测3年内急性冠状动脉综合征中的应用

急性冠状动脉综合征(ACS)往往是冠状动脉疾病(CAD)的首要临床表现,也是世界上大多数人死亡的主要原因。

European Radiology:CT放射组学列线图对腭扁桃体鳞状细胞癌和非霍奇金淋巴瘤的鉴别诊断

鳞状细胞癌(SCC)是头颈部最常见的恶性肿瘤,而非霍奇金淋巴瘤(NHL)是第二常见的肿瘤。腭扁桃体是头颈部SCC和NHL最常见的解剖学部位。这

Eur Radiol:放射组学模型中CT层厚预测非小细胞肺癌生存率的影响

在临床实践中,不同机构之间用于获取图像的CT层厚度通常有所差别,用于放射组学分析的最佳CT层厚度尚未确定。

Eur Radiol:由CT放射组学特征来预测神经母细胞瘤MYCN扩增

神经母细胞瘤是儿童最常见的颅外实性肿瘤。在20-30%的神经母细胞瘤中可检测到MYCN扩增(MNA),其与肿瘤侵袭行为和不良预后有很强的相关性。

Euro Radio:深度学习+放射组学!让软组织肉瘤复发无处遁形!

软组织肉瘤(STS)起源于间叶组织,其组织学成分复杂,临床表现多样,占成人癌症总发病率的1%。现阶段,根治性切除术是STS患者首选治疗手段。